Table 2.
Primary analysis of primary outcome. All treatment estimates are reported with adjustment for baseline values. Raw data expressed as median (inter-quartile range [IQR]). Number of individuals contributing to each analysis by treatment group and overall: overall: 123; placebo: 66; sildenafil: 57. CICU, cardiac ICU.
| Analysis | Randomised to placebo (n=67) |
Randomised to sildenafil (n=58) |
Time effect |
|||
|---|---|---|---|---|---|---|
| Median (μmol L−1) | (IQR) (μmol L−1) | Median (μmol L−1) | (IQR) (μmol L−1) | Adjusted mean difference (95% confidence intervals) | P-value | |
| Primary intention to treat | ||||||
| Baseline | 89 | (73 103) | 92 | (79 110) | ||
| CICU | 91.5 | (80 112) | 95.5 | (79 118) | Reference group | |
| 6–12 h | 101 | (84 127) | 104.5 | (84 129) | 8.16 (3.32, 13.00) | 0.001 |
| 24 h | 99 | (79 127) | 106 | (87 138) | 13.19 (8.36, 18.01) | <0.001 |
| 48 h | 100 | (82 139) | 107.5 | (86 153) | 18.88 (14.05, 23.7) | <0.001 |
| 72 h | 96.5 | (76 117) | 108 | (88 137) | 12.04 (6.96, 17.13) | <0.001 |
| 96 h | 97 | (78 112) | 110 | (89 131) | 6.95 (1.84, 12.06) | 0.008 |
| Treatment effect | ||||||
| Adjusted mean difference (95% confidence interval) | P-value | |||||
| Intervention (sildenafil) | 0.88 (–5.82, 7.59) | 0.797 | ||||